Evidence map›Paper›PMID 40647525›Full record

ReviewCancers2025

Infection Biomarkers in Children with Chemotherapy-Induced Severe Neutropenia.

Wioletta Bal, Zuzanna Piasecka, Klaudia Szuler, Radosław Chaber

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Wioletta BalDepartment of Pediatrics, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszow, Poland.
Zuzanna PiaseckaDepartment of Pediatrics, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszow, Poland.ORCID 0000-0001-7896-0907
Klaudia SzulerDepartment of Pediatrics, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszow, Poland.
Radosław ChaberDepartment of Pediatrics, Faculty of Medicine, University of Rzeszow, 35-310 Rzeszow, Poland.ORCID 0000-0002-6862-9142

Funding

University of Rzeszów none
6 · The paper itself

Abstract

BACKGROUND/

objectivesFebrile neutropenia is a frequent and potentially life-threatening complication in pediatric oncology patients receiving chemotherapy. Due to profound immunosuppression, early diagnosis of infections remains a major clinical challenge. This review evaluates the diagnostic and prognostic utility of infection biomarkers in children with chemotherapy-induced severe neutropenia.

methodsWe reviewed clinical studies that assessed the diagnostic performance of inflammatory biomarkers-including C-reactive protein (CRP), procalcitonin (PCT), interleukins (IL-6, IL-8, IL-10), and others-in pediatric febrile neutropenia. The review includes data on sensitivity, specificity, predictive value, and clinical applications.

resultsCRP remains a common but nonspecific marker, often insufficient for early stratification. PCT showed consistently high negative predictive value and early responsiveness to bacterial infections. IL-6 and IL-10 demonstrated strong early diagnostic accuracy in the early phase (AUC > 0.80 in multiple studies) and were particularly useful in predicting septic shock when combined. IL-8, while less specific, may help rule out infection when levels are low. Emerging biomarkers such as presepsin, MR-proADM, and PSP showed promising diagnostic performance. Presepsin achieved near-perfect accuracy in some cohorts (AUC up to 0.996), outperforming CRP and PCT, though its ability to discriminate bacteremia at fever onset varied. MR-proADM demonstrated consistent AUCs above 0.75 and may support early sepsis identification. PSP was associated with significantly elevated levels in sepsis. Additional novel markers-including sTNFR-II, sIL-2R, IP-10, Flt-3L, MCP-1-a, and MBL-showed encouraging diagnostic profiles in individual studies, particularly due to high specificity, but require external validation. G-CSF also emerged as a promising candidate in multimarker models. In contrast, TNF-α and IL-1β displayed limited utility as standalone indicators.

conclusionsBiomarkers such as PCT, IL-6, Il-8, and IL-10 offer valuable tools for early infection detection and risk stratification in pediatric febrile neutropenia. Emerging markers-including presepsin, MR-proADM, and PSP-further enhance diagnostic precision and may support early identification of sepsis. Multimarker strategies, particularly those incorporating presepsin, IL-10, or MR-proADM, show potential to improve diagnostic performance beyond conventional markers. Further prospective validation is needed to optimize clinical implementation and guide personalized treatment decisions.

Indexed as

bacteriemiabiomarkerchildrenfebrile neutropeniasepsis

Identifiers

PMID40647525
PMCPMC12249278

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.